Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 14 of 14

List	Outcome	Time frame	Description
Primary	Rate of chemotherapy-induced vomiting (CIV) control (complete plus partial control)	up to 8 days	Complete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during the phase. Partial CIV is defined as no more than 2 vomits or retches during any 24-hour period.
Primary	Rate of CIV control during the acute phase	up to 8 days	Partial control is defined as no more than two vomits or retches during any 24-hr period
Secondary	complete and partial CINV control	up to 1 month	Complete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during phase, Partial control is defined as no more than two vomits or retches during any 24-hr period
Secondary	Safety profile of olanzapine based on toxicities	up to 1 month	Based on descriptive statistics on reported toxicities.
Secondary	Safety profile of olanzapine based on weight	up to 1 month	Based on descriptive statistics on reported body weight
Secondary	Safety profile of olanzapine based on Pediatric Adverse Event Rating Scale (PAERs)	up to 1 month	Based on descriptive statistics on reported PAERs, will describe the most reported and most bothersome adverse events reported in the PAERs questionnaire.
Secondary	Safety profile of olanzapine based on prolactin	up to 1 month	Based on descriptive statistics on reported prolactin, will report incidence of abnormal prolactin values comparing the two arms
Secondary	Safety profile of olanzapine based on amylase	up to 1 month	Based on descriptive statistics on reported amylase, will report incidence of abnormal amylase values comparing the two arms
Secondary	Safety profile of olanzapine based on creatine phophotase	up to 1 month	Based on descriptive statistics on reported creatine phophotase, will report incidence of abnormal creatine phophotase values comparing the two arms
Secondary	Safety profile of olanzapine based on triglycerides	up to 1 month	Based on descriptive statistics on reported triglycerides, will report incidence of abnormal triglyceride values comparing the two arms
Secondary	Impact of olanzapine on HSCT outcomes on incidence of veno-occlusive disease	From first HSCT conditioning dose until 100 days post-HSCT	Looking at incidence of veno-occlusive disease
Secondary	Impact of olanzapine on HSCT outcomes on incidence of GVHD	From first HSCT conditioning dose until 100 days post-HSCT	Looking at incidence of GVHD between the two arms
Secondary	Impact of olanzapine on HSCT outcomes on severity of GVHD	From first HSCT conditioning dose until 100 days post-HSCT	Comparing the incidence of the different maximal grades of GVHD between the two arms
Secondary	Association between PeNAT and MASCC Antiemesis Tool (MAT) scores	up to 1 month	taking maximum daily PeNAT scale score and maximum nausea experience in MAT will estimate the degree of association between PeNAT and MAT

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03118986/registered

API reference For AI assistants